0.8160EUR-2.28%Mkt Cap: 226.22M EURP/E: —Last update: 2026-06-01
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II cl…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap226.22M EUR
Enterprise Value118.89M EUR
Revenue (TTM)7.21M EUR
Gross Profit-26.69M EUR
Net Income (TTM)-37.52M EUR
Revenue/Share0.0500 EUR
Last Price0.8160 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees145
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0005175080
Valuation
P/E (Trailing)—
P/E (Forward)-3.80
PEG3.08
EV/EBITDA-3.52
EV/Revenue16.49
P/S32.11
P/B1.88
EPS (TTM)-0.26
EPS (Forward)-0.22
52W Range
0.726012% of range1.500
52W High1.500 EUR
52W Low0.7260 EUR
Profitability
Gross Margin0.00%
Oper. Margin-684.11%
EBITDA Margin0.00%
Profit Margin-7657.96%
ROE-30.82%
ROA-27.03%
Growth
Revenue Growth-12.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-37.05M EUR
CapEx (TTM)842.00K EUR
FCF Margin-348.38%
FCF Yield-11.10%
Net Debt-109.80M EUR
Net Debt/EBITDA3.25
Balance Sheet
Debt/Equity0.00
Current Ratio9.62
Quick Ratio9.55
Book Value/Sh0.4440 EUR
Cash/Share0.4080 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)1.100 EUR
Target Range1.100 EUR – 1.100 EUR
# Analysts1
Ownership
Shares Out.277.23M
Float176.87M
Insiders34.96%
Institutions0.09%
Technical
SMA 500.7769 (+5.0%)
SMA 2000.9774 (-16.5%)
Beta0.73
S&P 52W Chg27.94%
Avg Vol (30d)51.73K
Avg Vol (10d)42.36K
Technical Indicators
RSI (14)62.3
MACD0.0169
MACD Signal0.0162
MACD Hist.+0.0007
BB Upper0.8788 EUR
BB Middle0.8135 EUR
BB Lower0.7483 EUR
BB Width16.04%
ATR (14)0.0206 EUR
Vol Ratio (20d)0.35x